FDA Drug Safety Podcast: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone

On October 26, 2015 FDA announced an FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease.

Source: FDA Drug Safety Podcasts - November 6, 2015 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts